BJMO - volume 12, issue 3, february 2018
Katleen Janssens , Katrien Clotman , P. Specenier MD, PhD, C. De Block
BJMO - volume 12, issue 3, february 2018
E. Roets , Karina Tukanova , A. Govarts , P. Specenier MD, PhD
BJMO - volume 12, issue 3, february 2018
N. van den Eede MD, P. Specenier MD, PhD, A. de Paepe MD
BJMO - volume 12, issue 1, february 2018
P. Specenier MD, PhD
Overview of Belgian reimbursement news.
(BELG J MED ONCOL 2018;12(1):33–34)
Read moreBJMO - volume 11, issue 8, december 2017
A.R. Garcia MD, C. van Laer MD, D. van den Weyngaert MD, T. van den Wyngaert MD, PhD, M. Lammens MD, PhD, P. Specenier MD, PhD, J.B. Vermorken MD, PhD
The prognosis of patients with advanced malignant salivary gland cancer is usually poor. Systemic therapy combined with best supportive care is recommended for patients with metastatic or recurrent advanced salivary gland cancer ineligible for surgery or radiotherapy. Sensitivity to chemotherapy is thought to be histotype specific. However, to date, none of the systemic therapies, whether cytotoxic or non cytotoxic, can be considered standard for these tumours.
We report the case of a 43 year-old male patient with a third (loco)regional recurrence and metastases in lymph nodes below the clavicles of a mucoepidermoid carcinoma of the right parotid gland. He participated in a feasibility study and was treated with 3-weekly cycles of docetaxel, cisplatin, 5-fluorouracil plus weekly cetuximab (TPFE). After four TPFE cycles, additional radiation was given to the left neck. A complete response was reached which is ongoing for ten years. TPFE induced acute toxicities: skin rash grade 3, hypotension grade 3, neutropenia grade 3, anaemia grade 2 and alopecia grade 2. This observation underlines the importance of offering patients the possibility to participate in clinical trials. International collaboration for rare head and neck cancers, such as mucoepidermoid carcinoma, is urgently needed.
(BELG J MED ONCOL 2017;11(8):386-392)
Read moreBJMO - volume 11, issue 7, november 2017
P. Specenier MD, PhD
BJMO - volume 11, issue 6, october 2017
P. Specenier MD, PhD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2017;11(6):292)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
